Merck to Move Global Headquarters Within New Jersey

  Merck to Move Global Headquarters Within New Jersey

 Company cites ongoing facilities consolidation and reiterates commitment to
                          reduce operating expenses

Business Wire

WHITEHOUSE STATION, N.J. -- October 09, 2012

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today
announced plans to move the company's global headquarters within the state
from Whitehouse Station, N.J. to its existing property in Summit, N.J., which
currently houses research, manufacturing, animal health and consumer care
operations and is home to 1,800 people. The company will close its current
headquarters building in Whitehouse Station, N.J. The transition process is
expected to begin in 2014 and be completed in mid-2015.

The headquarters relocation is part of the company's ongoing program to
consolidate its global real estate footprint and lower its annual operating
expenses, following its merger with Schering Plough in 2009. The Summit
location was selected as the site for Merck’s new headquarters because it is a
strategic, multi-use site with excess work-space capacity and is adjacent to
major transportation hubs and desirable urban centers.

"The relocation of our headquarters will help us achieve our future vision,
reduce the size of our operating footprint, and increase agility as we adapt
to our changingbusiness environment," said Kenneth C. Frazier, chairman and
chief executive officer of Merck.

About 2,000 employees and contractors currently situated at the Whitehouse
Station global headquarters building either will move to the new facilities in
Summit or to other nearby facilities such as those in Branchburg, N.J. and
Cokesbury, N.J.

Merck has been headquartered in Whitehouse Station since 1992. Prior to that,
the company was headquartered in Rahway, N.J.

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit and
connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. Such statements may include, but are not limited to,
statements about the benefits of the merger between Merck and Schering-Plough,
including future financial and operating results, the combined company’s
plans, objectives, expectations and intentions and other statements that are
not historical facts. Such statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. Actual results may differ from those set forth in the
forward-looking statements.

The following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the possibility that all of
the expected synergies from the merger of Merck and Schering-Plough will not
be realized, or will not be realized within the expected time period; the
impact of pharmaceutical industry regulation and health care legislation in
the United States and internationally; Merck’s ability to accurately predict
future market conditions; dependence on the effectiveness of Merck’s patents
and other protections for innovative products; and the exposure to litigation
and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2011
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site


Media Contacts:
Ron Rogers, 908-423-6449
Steve Cragle, 908-423-3461
Investor Contacts:
Carol Ferguson, 908-423-4465
Alex Kelly, 908-423-5185
Press spacebar to pause and continue. Press esc to stop.